Carillon Tower Advisers released its third-quarter 2025 investor letter, noting equity market rally, AI enthusiasm, and mid-cap stock gains. The Russell Midcap Growth Index underperformed the Value Index. The letter detailed views on Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors, offering insight into the fund’s top 5 holdings for 2025.

In its third-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company. INSM had a one-month return of 25.19% and shares rose 173.43% over 52 weeks. On November 24, 2025, INSM stock closed at $206.93 per share, with a market cap of $44.133 billion.

Insmed Incorporated (NASDAQ:INSM) develops therapeutic products for lung diseases. The company’s Brinsupri product approval for non-cystic fibrosis bronchiectasis treatment marked a milestone, driving stock performance. Insmed (INSM) Soars After Raising $650 million in funding, though not listed in the 30 Most Popular Stocks Among Hedge Funds due to AI stock potential.

Read more at Yahoo Finance: Insmed (INSM) Rose Following Drug Approval